Hepalink

Hepalink, founded in Shenzhen, China in 1998, was established with the mission of "bringing blessings to patients and becoming an internationally leading pharmaceutical enterprise," as envisioned by its founders. Through relentless efforts, Hepalink has successfully built an integrated and secure supply chain, becoming the world's largest supplier of heparin sodium active pharmaceutical ingredients (API) and the fourth-largest provider of enoxaparin formulations globally. In the European Union, formulations under the "Inhixa" and "Neoparin" brands are being commercialized on a large scale. In China, the "Prolongjing" brand has become the second-largest market brand, next only to the original research brand. Beyond these regions, enoxaparin formulations have also been approved for marketing in dozens of other countries and regions. The heparin full-industry-chain business is generating steadily growing cash flow for the company.While building the cornerstone of the company’s development—deep cultivation of the heparin full-industry chain—the founder, an expert in glyco-biochemistry, has led the global R&D team in consistently researching the roles of heparin and its derivatives at the molecular biology level, particularly in the field of immune regulation mechanisms. This research has laid the scientific foundation for the company’s innovative drug pipeline—focusing on developing, exploring, and investing in first-in-class drugs targeting cardiovascular and oncology diseases caused by immune imbalance, addressing significant unmet clinical needs with high mortality rates. The company currently holds global rights to multiple first-in-class innovative drugs and Greater China commercialization rights to several late-stage clinical assets. As these innovative drugs gradually complete clinical trials worldwide, not only will our global rights be realized, but more importantly, the realization of Greater China commercialization rights is also within reach.To broaden the scope of innovative candidate screening and enable more precise selection of new drugs, as well as to accelerate the development progress of existing pipeline candidates, the company acquired Cytovance, a biologics Contract Development and Manufacturing Organization (CDMO) with globally leading and unique technological capabilities. Our biologics CDMO platform excels in microbial and mammalian cell operations and focuses on the rapidly growing gene therapy market opportunities. With its high-quality and unique technical services, it has earned the trust of heavyweight clients worldwide, becoming another rapidly growing cash-flow business for the company.The comprehensive management system and best practices for global drug R&D, rapid translation, production operations, and marketing—especially the highly innovative R&D pipeline—and the high-growth CDMO business that empowers innovation, are organically combined to form Hepalink's future-oriented development advantages.